Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date of Report: May 9, 2024
Reporting Period: Event-based report regarding a scheduled investor communication.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report announcing a corporate event rather than a periodic financial report.
Material Changes
No material financial changes or operational updates are reported in this filing. The sole material event is the announcement of an upcoming webcast to review clinical trial data.
Guidance, Outlook, and Management Commentary
- Upcoming Event: The Company will host a webcast and conference call on Thursday, May 23, 2024, at 4:30 p.m. Eastern Time.
- Subject Matter: The call will review interim data from the open-label Phase IIa study of SPN-817 for the treatment of treatment-resistant seizures.
- Access: A live webcast with presentation slides will be available at www.supernus.com and archived for 60 days.
- Forward-Looking Statements: The filing includes standard disclaimers regarding forward-looking statements, noting they are subject to risks and uncertainties detailed in the Company's Form 10-K for the fiscal year ended December 31, 2023.
Investor Verification Checklist
- Verify the date and time of the upcoming webcast (May 23, 2024, 4:30 p.m. ET).
- Confirm the specific clinical trial phase and drug candidate (Phase IIa study of SPN-817).
- Review the press release furnished as Exhibit 99.1 for additional context on the study design.
- Consult the most recent Form 10-K for detailed risk factors associated with clinical development.